Skip to main content

14.08.2019 | Original Article

Epidemiological survey and risk factor analysis of dialysis-related amyloidosis including destructive spondyloarthropathy, dialysis amyloid arthropathy, and carpal tunnel syndrome

verfasst von: Atsushi Tagami, Masato Tomita, Shinji Adachi, Keiichi Tsuda, Shuta Yamada, Koh Chiba, Narihiro Okazaki, Akihiko Yonekura, Ritsu Tsujimoto, Shiro Kajiyama, Shohei Matsubayashi, Takashi Miyamoto, Yasushi Mochizuki, Kojiro Ohba, Makoto Osaki

Erschienen in: Journal of Bone and Mineral Metabolism

Einloggen, um Zugang zu erhalten

Abstract

The RDT population, initially at 215 patients, exceeded 300,000 in 2011, with a total of 329,609 patients at the end of December 2016. In our Institute, the number of patients with destructive spondylosis is increasing with the increase in the number of dialysis patients in Japan. We had 14 Cases in the 1990s, and then 82 cases in the 2000s and have already had 131 cases in the 2010s. The purpose of this study was to investigate the incidence of dialysis-related amyloidosis (DRA) such as destructive spondyloarthropathy (DSA), dialysis amyloid arthropathy (DAA), and carpal tunnel syndrome (CTS). In addition, another purpose was to examine the risk factors of the DRA. DAA made its own assessment on radiographs based on stage. Survey items were patient’s basic data, laboratory data and X-ray view. Patientʼs basic data included such as sex, age, height, and weight and RDT-related factors such as kidney disease that led to RDT, age at start of RDT, RDT history, medical history (past and present), and history of surgery. The frequency of DRA was examined by medical history and radiological examination in 199 dialysis patients who obtained informed consent. The patients were divided into two groups according to the presence or absence of DRA, and risk factors of DRA were investigated from the medical history, basic data of patients, and blood tests. Of the 199 patients on regular dialysis therapy, 41 (20.6%) showed DRA. Based on the X-ray images, 21 patients (10.6%) showed DSA, while 22 patients (11.1%) showed DAA. Sixteen patients (8.0%) had CTS, determined through a history of surgery. Regarding overlap of conditions, 14 had both DSA and DAA, 3 had both DSA and CTS, and 2 had both DAA and CTS. There were statistically significant differences between the two groups in the cause of disease in Chronic glomerulonephritis and Diabetic Nephropathy, age at the start of RDT, period of RDT, body weight, blood platelet count, and blood Ca level. When multivariate analysis was performed on these items, statistical differences were recognized only during the dialysis period. In conclusion, long dialysis period was a risk factor for DRA.
Literatur
1.
Zurück zum Zitat The Japanese Society for Dialysis Therapy An overview of regular dialysis treatment in Japan as of Dec. 31, 2016 The Japanese Society for Dialysis Therapy An overview of regular dialysis treatment in Japan as of Dec. 31, 2016
2.
3.
Zurück zum Zitat Chin M, Hase H, Miyamoto T, Tsuji Y (2006) Radiological grading of cervical destructive spondyloarthropathy in long-term hemodialysis patients. J Spinal Disord Tech 19:430–435CrossRef Chin M, Hase H, Miyamoto T, Tsuji Y (2006) Radiological grading of cervical destructive spondyloarthropathy in long-term hemodialysis patients. J Spinal Disord Tech 19:430–435CrossRef
5.
Zurück zum Zitat Lee Jon Choon E, Secretary NA, Choong Hui Lin L, et al (2014) Singapore renal registry annual registry report 1999–2013 (Preliminary). Health Promotion Board. National Registry of Diseases Office (NRDO) Lee Jon Choon E, Secretary NA, Choong Hui Lin L, et al (2014) Singapore renal registry annual registry report 1999–2013 (Preliminary). Health Promotion Board. National Registry of Diseases Office (NRDO)
7.
Zurück zum Zitat Hughes EA, Hammond C, Cresswell P (1997) Misfolded major histocompatibility complex class I heavy chains are translocated into the cytoplasm and degraded by the proteasome. Immunology 94:1896–1901 Hughes EA, Hammond C, Cresswell P (1997) Misfolded major histocompatibility complex class I heavy chains are translocated into the cytoplasm and degraded by the proteasome. Immunology 94:1896–1901
10.
Zurück zum Zitat Kuntz D, Naveau B, Bardin T, Drueke T, Treves R, Dryll A (1984) Destructive spondylarthropathy in hemodialyzed patients. A new syndrome. Arthritis Rheum 27:369–375CrossRef Kuntz D, Naveau B, Bardin T, Drueke T, Treves R, Dryll A (1984) Destructive spondylarthropathy in hemodialyzed patients. A new syndrome. Arthritis Rheum 27:369–375CrossRef
11.
Zurück zum Zitat Fiocchi O, Bedani PL, Orzincolo C, Storari A, Cavazzini PL, Malacarne F, Farinelli A (1989) Radiological features of dialysis amyloid spondyloarthropathy. Int J Artif Organs 12:216–222CrossRef Fiocchi O, Bedani PL, Orzincolo C, Storari A, Cavazzini PL, Malacarne F, Farinelli A (1989) Radiological features of dialysis amyloid spondyloarthropathy. Int J Artif Organs 12:216–222CrossRef
13.
Zurück zum Zitat Yamamoto T, Matsuyama Y, Tsuji T, Nakamura H, Yanase M, Ishiguro N (2005) Destructive spondyloarthropathy in hemodialysis patients comparison between patients with and those without destructive spondyloarthropathy. J Spinal Disord Tech 18:283–285CrossRef Yamamoto T, Matsuyama Y, Tsuji T, Nakamura H, Yanase M, Ishiguro N (2005) Destructive spondyloarthropathy in hemodialysis patients comparison between patients with and those without destructive spondyloarthropathy. J Spinal Disord Tech 18:283–285CrossRef
15.
Zurück zum Zitat Bardin T, Kuntz D (1987) The arthropathy of chronic haemodialysis. Clin Exp Rheumatol 5:379–386 Bardin T, Kuntz D (1987) The arthropathy of chronic haemodialysis. Clin Exp Rheumatol 5:379–386
20.
Zurück zum Zitat Otsubo S, Kimata N, Okutsu I, Oshikawa K, Ueda S, Sugimoto H, Mitobe M, Uchida K, Otsubo K, Nitta K, Akiba T (2009) Characteristics of dialysis-related amyloidosis in patients on haemodialysis therapy for more than 30 years. Nephrol Dial Transplant 24:1593–1598. https://doi.org/10.1093/ndt/gfn706 CrossRefPubMed Otsubo S, Kimata N, Okutsu I, Oshikawa K, Ueda S, Sugimoto H, Mitobe M, Uchida K, Otsubo K, Nitta K, Akiba T (2009) Characteristics of dialysis-related amyloidosis in patients on haemodialysis therapy for more than 30 years. Nephrol Dial Transplant 24:1593–1598. https://​doi.​org/​10.​1093/​ndt/​gfn706 CrossRefPubMed
21.
Zurück zum Zitat Kessler M, Netter P, Azoulay E, Mayeux D, Pere P, Gaucher A (1992) Dialysis-associated arthropathy: a multicentre survey of 171 patients receiving haemodialysis for over 10 years. The Co-operative Group on Dialysis-associated Arthropathy. Br J Rheumatol 31:157–162CrossRef Kessler M, Netter P, Azoulay E, Mayeux D, Pere P, Gaucher A (1992) Dialysis-associated arthropathy: a multicentre survey of 171 patients receiving haemodialysis for over 10 years. The Co-operative Group on Dialysis-associated Arthropathy. Br J Rheumatol 31:157–162CrossRef
Metadaten
Titel
Epidemiological survey and risk factor analysis of dialysis-related amyloidosis including destructive spondyloarthropathy, dialysis amyloid arthropathy, and carpal tunnel syndrome
verfasst von
Atsushi Tagami
Masato Tomita
Shinji Adachi
Keiichi Tsuda
Shuta Yamada
Koh Chiba
Narihiro Okazaki
Akihiko Yonekura
Ritsu Tsujimoto
Shiro Kajiyama
Shohei Matsubayashi
Takashi Miyamoto
Yasushi Mochizuki
Kojiro Ohba
Makoto Osaki
Publikationsdatum
14.08.2019
Verlag
Springer Japan
Erschienen in
Journal of Bone and Mineral Metabolism
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-019-01028-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.